Javier Oesterheld

651 total citations
18 papers, 217 citations indexed

About

Javier Oesterheld is a scholar working on Oncology, Neurology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Javier Oesterheld has authored 18 papers receiving a total of 217 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Neurology and 6 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Javier Oesterheld's work include Neuroblastoma Research and Treatments (7 papers), Acute Lymphoblastic Leukemia research (5 papers) and Acute Myeloid Leukemia Research (4 papers). Javier Oesterheld is often cited by papers focused on Neuroblastoma Research and Treatments (7 papers), Acute Lymphoblastic Leukemia research (5 papers) and Acute Myeloid Leukemia Research (4 papers). Javier Oesterheld collaborates with scholars based in United States, Germany and Canada. Javier Oesterheld's co-authors include Steven G. DuBois, Giselle L. Saulnier Sholler, William Roberts, Keith J. August, Colleen Annesley, Valerie I. Brown, Randal K. Wada, Elena Eckroth, Peter E. Zage and Todd M. Cooper and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Javier Oesterheld

17 papers receiving 214 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Javier Oesterheld United States 8 105 67 54 40 38 18 217
Ari Pelcovits United States 7 121 1.2× 110 1.6× 19 0.4× 68 1.7× 21 0.6× 23 264
Alan C. Homans United States 8 78 0.7× 39 0.6× 71 1.3× 33 0.8× 22 0.6× 13 259
Terukazu Enami Japan 10 76 0.7× 76 1.1× 21 0.4× 53 1.3× 12 0.3× 16 225
Lianna J. Marks United States 7 34 0.3× 31 0.5× 31 0.6× 39 1.0× 11 0.3× 21 137
Brett T. Brinker United States 5 65 0.6× 37 0.6× 12 0.2× 41 1.0× 11 0.3× 5 133
Kerstin Busch Germany 5 53 0.5× 16 0.2× 30 0.6× 42 1.1× 27 0.7× 5 168
Margarita Blanes Spain 7 127 1.2× 94 1.4× 8 0.1× 70 1.8× 15 0.4× 13 287
Eugenia Franchini Italy 6 36 0.3× 62 0.9× 14 0.3× 28 0.7× 9 0.2× 11 150
Nicole Paul United States 5 37 0.4× 30 0.4× 33 0.6× 105 2.6× 20 0.5× 5 291
Xinping Zhou China 8 92 0.9× 152 2.3× 9 0.2× 57 1.4× 7 0.2× 43 290

Countries citing papers authored by Javier Oesterheld

Since Specialization
Citations

This map shows the geographic impact of Javier Oesterheld's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Javier Oesterheld with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Javier Oesterheld more than expected).

Fields of papers citing papers by Javier Oesterheld

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Javier Oesterheld. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Javier Oesterheld. The network helps show where Javier Oesterheld may publish in the future.

Co-authorship network of co-authors of Javier Oesterheld

This figure shows the co-authorship network connecting the top 25 collaborators of Javier Oesterheld. A scholar is included among the top collaborators of Javier Oesterheld based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Javier Oesterheld. Javier Oesterheld is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Wells, Kim E., Maddeboina Krishnaiah, Kimberly Q. McKinney, et al.. (2025). Abstract 3006: Efficacy of novel CDK9/CDK4/6/PI3K triple inhibitors, LCI133 and LCI139, in Ewing sarcoma. Cancer Research. 85(8_Supplement_1). 3006–3006.
2.
3.
Oesterheld, Javier, et al.. (2024). Guidelines for outpatient administration of naxitamab: Experience from Atrium Health Levine Children's Hospital. Cancer Medicine. 13(3). e7045–e7045. 3 indexed citations
4.
Oesterheld, Javier, William S. Ferguson, Jacqueline M. Kraveka, et al.. (2023). Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score–Matched Survival Outcome Comparisons. Journal of Clinical Oncology. 42(1). 90–102. 28 indexed citations
5.
Brown, Dennis, et al.. (2023). A pilot clinical study of oral irinotecan HCl (VAL-413) in patients with recurrent pediatric solid tumors.. Journal of Clinical Oncology. 41(16_suppl). TPS10073–TPS10073. 1 indexed citations
6.
Oesterheld, Javier, Genevieve Bergendahl, Donald A. Berry, et al.. (2022). Matched external control analysis of event-free survival (EFS) in patients with high-risk neuroblastoma (HRNB) receiving eflornithine (DFMO) maintenance.. Journal of Clinical Oncology. 40(16_suppl). 10010–10010. 1 indexed citations
7.
Brown, Dennis, James I. Geller, Patrick A. Thompson, et al.. (2022). A pilot clinical study of VAL-413 (oral irinotecan HCl) in patients with recurrent pediatric solid tumors.. Journal of Clinical Oncology. 40(16_suppl). TPS10063–TPS10063. 1 indexed citations
8.
Tan, Serena Y., Alyaa Al‐Ibraheemi, Wolfgang Ahrens, et al.. (2021). ALK rearrangements in infantile fibrosarcoma‐like spindle cell tumours of soft tissue and kidney. Histopathology. 80(4). 698–707. 17 indexed citations
9.
Oesterheld, Javier, Damon R. Reed, Bhuvana A. Setty, et al.. (2020). Phase II trial of gemcitabine and nab‐paclitaxel in patients with recurrent Ewing sarcoma: A report from the National Pediatric Cancer Foundation. Pediatric Blood & Cancer. 67(7). e28370–e28370. 16 indexed citations
10.
Lewis, Elizabeth C., Jacqueline M. Kraveka, William S. Ferguson, et al.. (2020). A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high‐risk neuroblastoma. International Journal of Cancer. 147(11). 3152–3159. 45 indexed citations
11.
Hochberg, Jessica, Javier Oesterheld, Allyson Flower, et al.. (2019). Phase II results of mitoxantrone in combination with clofarabine in children with relapsed/refractory acute leukemia.. Journal of Clinical Oncology. 37(15_suppl). 7036–7036. 1 indexed citations
12.
Messinger, Yoav H., Jessica Boklan, Jeffrey L. Goldberg, et al.. (2017). Combination of clofarabine, cyclophosphamide, and etoposide for relapsed or refractory childhood and adolescent acute myeloid leukemia. Pediatric Hematology and Oncology. 34(4). 187–198. 13 indexed citations
13.
Cooper, Todd M., Elena Eckroth, Jemily Malvar, et al.. (2016). A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. Clinical Cancer Research. 22(16). 4014–4022. 56 indexed citations
14.
Eckrich, Michael J., Carrie Barnhart, Stacy Epstein, et al.. (2015). Successful Use of Cryopreservation and Shipping of CD34-Selected Mismatched Related Donor Grafts for Treatment of Children. Biology of Blood and Marrow Transplantation. 21(2). S153–S154. 1 indexed citations
15.
Coulter, Donald W., Christine M. Walko, Jai N. Patel, et al.. (2013). Valproic acid reduces the tolerability of temsirolimus in children and adolescents with solid tumors. Anti-Cancer Drugs. 24(4). 415–421. 14 indexed citations
16.
Gilman, Andrew L., Michael J. Eckrich, Stacy Epstein, et al.. (2013). CD34-Selected, T Cell-Depleted Alternative Donor Stem Cell Transplantation For Children. Blood. 122(21). 2064–2064. 1 indexed citations
17.
18.
Monaco, Sara E., Vundavalli V. Murty, Virginia Donovan, et al.. (2006). Pediatric ALK+ anaplastic large cell lymphoma with t(3;8)(q26.2;q24) translocation and c‐myc rearrangement terminating in a leukemic phase. American Journal of Hematology. 82(1). 59–64. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ari Pelcovits Breakdown of academic impact, for papers by Alan C. Homans Breakdown of academic impact, for papers by Terukazu Enami Breakdown of academic impact, for papers by Lianna J. Marks Breakdown of academic impact, for papers by Brett T. Brinker Breakdown of academic impact, for papers by Kerstin Busch Breakdown of academic impact, for papers by Margarita Blanes Breakdown of academic impact, for papers by Eugenia Franchini Breakdown of academic impact, for papers by Nicole Paul Breakdown of academic impact, for papers by Xinping Zhou
Rankless by CCL
2026